Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Silo Pharma confirmed positive nine-month stability data for its investigational PTSD treatment SPC-15, supporting the advancement of its IND-enabling development program. The data demonstrated that the formulation maintains integrity under long-term and accelerated storage conditions, validating adherence to cGMP standards required for regulatory submission.
Key figures
- Drug Name
- SPC-15
- Phase Of Trial
- Preclinical
- Stability duration months
- 9
- Accelerated stability months
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.